Cardiotoxicity of anticancer treatments

@article{Ewer2015CardiotoxicityOA,
  title={Cardiotoxicity of anticancer treatments},
  author={Michael S. Ewer and Steven M Ewer},
  journal={Nature Reviews Cardiology},
  year={2015},
  volume={12},
  pages={547-558}
}
  • M. Ewer, S. Ewer
  • Published 2015
  • Medicine, Biology
  • Nature Reviews Cardiology
Patients with cancer can experience adverse cardiovascular events secondary to the malignant process itself or its treatment. Patients with cancer might also have underlying cardiovascular illness, the consequences of which are often exacerbated by the stress of the tumour growth or its treatment. With the advent of new treatments and subsequent prolonged survival time, late effects of cancer treatment can become clinically evident decades after completion of therapy. The heart's extensive… 
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
  • J. Herrmann
  • Medicine, Biology
    Nature Reviews Cardiology
  • 2020
TLDR
The cardiotoxicity spectrum of cancer therapies has broadened and is gaining increasing importance with an ever-growing repertoire of therapeutics, and atrial fibrillation is emerging as the most relevant and practically challenging arrhythmia in patients with cancer.
Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection
TLDR
There is an urgent need for cardioprotective therapies to reduce the clinical and subclinical cardiotoxicity onset and progression and to limit the acute or chronic manifestation of cardiac damages.
Cardiovascular Effects of Cancer Therapy
Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity
TLDR
The progress of genetic research in illuminating the molecular mechanisms of cancer treatment-mediated cardiotoxicity is reviewed and insights for the research and development of new therapies to treat or even prevent cardiot toxicity in patients undergoing cancer treatment are provided.
Cardiooncology—dealing with modern drug treatment, long-term complications, and cancer survivorship
TLDR
This review focusses on acute and long-term cardiotoxic side effects of classical cytotoxic and selected modern drug treatments such as immune checkpoint inhibitors and discusses strategies for the diagnosis of treatment-related adverse cardiovascular effects in cancer patients.
Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy
TLDR
A focused review of the mechanisms proposed to underlie the development of anthracycline cardiomyopathy based on experimental data mostly in mouse models and insights into its pathogenesis may stimulate thedevelopment of new strategies to identify patients who are susceptible to anthrACYclineCardiotoxicities while permitting low cardiac risk patients to receive optimal treatment for their cancer.
Cardiovascular disease in survivors of childhood cancer
TLDR
A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no ‘safe’ dose of anthracyclines, and the use of dexrazoxane is advocated to limit the cardiotoxic effects of anthRacycline chemotherapy.
ATVB IN FOCUS: Cardiovascular Effects of Anticancer Treatments/Agents
TLDR
A focused review of the mechanisms proposed to underlie the development of anthracycline cardiomyopathy based on experimental data mostly in mouse models and insights into its pathogenesis may stimulate theDevelopment of new strategies to identify patients who are susceptible to anthrACYclineCardiotoxicities while permitting low cardiac risk patients to receive optimal treatment for their cancer.
Hypertension management in cardio-oncology
TLDR
Hypertension in cardio-oncology is a leading cause of morbidity and mortality in cancer survivors second only to recurrent cancer and should be managed utilising the same treatment guidelines for the general population.
Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients
TLDR
The authors describe the mechanisms of cardiotoxicity induced by anthracyclines, which can lead to cardiovascular problems in up to 48% of patients who take them, and outline the recent advances in immunotherapies, which have revolutionised anticancer therapies.
...
...

References

SHOWING 1-10 OF 125 REFERENCES
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
TLDR
In an effort to maximize both quality of life and survival, cardiologists and oncologists should collaborate with the aim of balancing the risks of cardiotoxicity with the benefits of oncologic therapy.
Cardiac Complications of Chemotherapy: Role of Biomarkers
TLDR
Cardiac troponin elevation during chemotherapy allows us to identify patients who are more prone to develop myocardial dysfunction and cardiac events during follow up, giving the chance for a cardioprotective strategy in a selected population.
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
TLDR
The most promising current strategies to limit or prevent anthracycline‐induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening are summarised.
Using cardiac biomarkers and treating cardiotoxicity in cancer.
TLDR
Cardiac troponin elevation during chemotherapy allows the identification of patients who are more prone to develop myocardial dysfunction and cardiac events during follow-up, giving the chance for a cardioprotective strategy in a selected population of cancer patients.
Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.
TLDR
This commentary highlights the key discussion points and overarching recommendations from a two-day workshop on the understanding of cancer treatment-related cardiotoxicity across basic and clinical science held in March 2013 in Bethesda, MD.
Radiation-associated cardiovascular disease.
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
  • M. Ewer, S. Lippman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Type I chemotherapyrelated cardiac dysfunction, which directly involves the myocardium, is manifested by a decreased left-ventricular ejection fraction, and which may progress to congestive heart failure; this form is the focus of this brief commentary.
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
TLDR
Late effects of anthracyclines are directly related to the degree of associated myocyte damage and include subclinical left ventricular dysfunction and overt heart failure and a common pathogenetic mechanism is proposed.
...
...